Lymph-node metastasis from gastric adenocarcinoma in a patient bearing a germ line missense variant MSH2 c.1808A > T (Asp603Val) responds to the immune checkpoint inhibitor pembrolizumab
Japanese Journal of Clinical Oncology · 2023
DOI: 10.1093/jjco/hyac183 ↗Kurz gefasst
Fallbericht in der Zeitschrift Japanese Journal of Clinical Oncology, 2023. Verfasst von Miki Kiyomiya und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Graduate School of Medicine, Akita University, Akita, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma. Die Arbeit nennt 17 Literaturangaben. Gefördert von: department's operating expenses, department’s operating expenses.
Abstract (Originalsprache)
We report the sensitivity of immune checkpoint inhibitors for tumors developing in a patient bearing the MSH2 c.1808A > T (Asp603Val) variant belonging to a pedigree of Lynch syndrome. This variant was previously thought to be of unknown significance, but we recently found that this missense mutation was likely pathogenic. At that time, there were no active members with malignancies that could be treated with chemotherapy. Thereafter, an 81-year-old woman bearing this variant, who was a cousin of the proband of this family, had multiple lymph node metastases from her resected gastric cancer. An immune checkpoint inhibitor, pembrolizumab, an anti-PD-1 antibody, was used to treat these tumors. After 3 months of treatment, almost all tumors disappeared, and elevated CA19–9 levels normalized. She survives over 15 months safely. It was indicated that the tumors bearing this germline variant were sensitive to pembrolizumab. This observation suggests that an MSH2 c.1808A > T (Asp603Val) variant induces mismatch repair deficiency, resulting in sensitization to immune checkpoint inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology, Graduate School of Medicine, Akita University, Akita, Japan.
- Department of Pathology, Akita University Hospital, Akita, Japan.
ORCID-Profile: Hiroyuki Shibata
Förderung
- department's operating expenses
- department’s operating expenses
Zitieren
APA
Kiyomiya, M., Fukuda, K., Shimazu, K., Yoshida, T., Taguchi, D., Shinozaki, H., Nanjyo, H., & Shibata, H. (2023). Lymph-node metastasis from gastric adenocarcinoma in a patient bearing a germ line missense variant MSH2 c.1808A > T (Asp603Val) responds to the immune checkpoint inhibitor pembrolizumab. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyac183
Vancouver
Kiyomiya M, Fukuda K, Shimazu K, Yoshida T, Taguchi D, Shinozaki H, et al. Lymph-node metastasis from gastric adenocarcinoma in a patient bearing a germ line missense variant MSH2 c.1808A > T (Asp603Val) responds to the immune checkpoint inhibitor pembrolizumab. Japanese Journal of Clinical Oncology. 2023. doi:10.1093/jjco/hyac183
BibTeX
@article{Kiyomiya2023,
author = {Kiyomiya, Miki and Fukuda, Koji and Shimazu, Kazuhiro and Yoshida, Taichi and Taguchi, Daiki and Shinozaki, Hanae and Nanjyo, Hiroshi and Shibata, Hiroyuki},
title = {Lymph-node metastasis from gastric adenocarcinoma in a patient bearing a germ line missense variant MSH2 c.1808A > T (Asp603Val) responds to the immune checkpoint inhibitor pembrolizumab},
journal = {Japanese Journal of Clinical Oncology},
year = {2023},
doi = {10.1093/jjco/hyac183}
}
EUVIMED